

Development of selective blockers for Ca²⁺-activated Cl⁻ channel using *Xenopus laevis* oocytes with an improved drug screening strategy

Soo-Jin Oh^{1,3}, Jung Hwan Park², Sungyu Han¹, Jae Kyun Lee², Eun Joo Roh² and C Justin Lee*¹

Address: ¹Center for Neural Science, Future Fusion Technology Laboratory, Korea Institute of Science and Technology (KIST), Seoul 136-791, Republic of Korea, ²Center for Chemoinformatics Research, Life Sciences Division, Korea Institute of Science and Technology (KIST), Seoul 136-791, Republic of Korea and ³Department of Cell and Developmental Biology, Dental Research Institute, School of Dentistry, Seoul National University, Seoul 110-740, Republic of Korea

Email: Soo-Jin Oh - osj@kist.re.kr; Jung Hwan Park - chemistpark@hanmail.net; Sungyu Han - hanpisa@hanmail.net; Jae Kyun Lee - j9601@kist.re.kr; Eun Joo Roh - r8636@kist.re.kr; C Justin Lee* - cjl@kist.re.kr

* Corresponding author

Published: 29 October 2008

Received: 15 October 2008

Molecular Brain 2008, 1:14 doi:10.1186/1756-6606-1-14

Accepted: 29 October 2008

This article is available from: <http://www.molecularbrain.com/content/1/1/14>

© 2008 Oh et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Ca²⁺-activated Cl⁻ channels (CaCCs) participate in many important physiological processes. However, the lack of effective and selective blockers has hindered the study of these channels, mostly due to the lack of good assay system. Here, we have developed a reliable drug screening method for better blockers of CaCCs, using the endogeneous CaCCs in *Xenopus laevis* oocytes and two-electrode voltage-clamp (TEVC) technique.

Results: Oocytes were prepared with a treatment of Ca²⁺ ionophore, which was followed by a treatment of thapsigargin which depletes Ca²⁺ stores to eliminate any contribution of Ca²⁺ release. TEVC was performed with micropipette containing chelerythrine to prevent PKC dependent run-up or run-down. Under these conditions, Ca²⁺-activated Cl⁻ currents induced by bath application of Ca²⁺ to oocytes showed stable peak amplitude when repetitively activated, allowing us to test several concentrations of a test compound from one oocyte. Inhibitory activities of commercially available blockers and synthesized anthranilic acid derivatives were tested using this method. As a result, newly synthesized *N*-(4-trifluoromethylphenyl)anthranilic acid with trifluoromethyl group (-CF₃) at *para* position on the benzene ring showed the lowest IC₅₀.

Conclusion: Our results provide an optimal drug screening strategy suitable for high throughput screening, and propose *N*-(4-trifluoromethylphenyl)anthranilic acid as an improved CaCC blocker.

Background

Ca²⁺-activated Cl⁻ channels (CaCCs) are anion-selective channels that can be activated by an increase in cytosolic Ca²⁺. CaCCs serve a number of important physiological roles in a variety of cell types. These functions include vas-

cular tone regulation, cardiac excitability, smooth muscle contraction, fast block of polyspermy in certain eggs [1]. CaCCs are also known to regulate epithelial secretion of electrolytes and water in kidneys, airways, intestines, pancreas and salivary glands [1]. In addition, CaCCs appear to

participate in signal processing of olfactory transduction, photo receptor light response, gustation and somesthetic sensation by regulating neuronal cell excitability. CaCC currents in non-sensory neurons of the spinal cord and the autonomic nervous system were also reported, and further investigation may prove an even more extensive expression in the nervous system [2]. Despite this physiological importance of CaCC, the channel remains poorly understood at the molecular, biophysical and pharmacological level, owing to the lack of specific pharmacological tools with high potent and selectivity. Currently available blockers require high concentrations to completely block CaCCs and are known to cause undesirable side effects and block other channels. For example, niflumic acid and 4,4'-diisothiocyanatostilbene-2,2'-disulphonic acid (DIDS) which are widely used to block CaCC also block volume-regulated anion channel (VRAC) in some cell types [3,4]. Niflumic acid, flufenamic acid and 5-nitro-2-(3-phenylpropylamino)-benzoic acid (NPPB) are shown to have a blocking effect on K⁺ channel current [5,6]. Niflumic acid, flufenamic acid and NPPB also cause an increase in intracellular Ca²⁺ concentration ([Ca²⁺]_i) in several cell types, which could elicit other cellular responses [7-11]. Therefore, due to these problems with low potency and selectivity, there is an eminent need for development of better blockers for CaCCs.

Xenopus laevis oocytes have been used widely in the field of electrophysiology to study the structure and the function of numerous ion channels and to screen for selective blockers. These oocytes express several native ion channels including CaCC in the plasma membrane [12], which are normally avoided when studying other ion channels by substituting Ca²⁺ with Ba²⁺ in the extracellular solution in attempt to prevent activation of endogenous CaCCs. These CaCCs have similar properties in many ways to those in cardiac muscle, smooth muscle, secretory epithelial cells and neurons [13]. There have been a numerous attempts to discover chemical compounds to block the endogenous CaCCs in *Xenopus laevis* oocytes using TEVC (two-electrode voltage clamp) technique. These studies reported half maximal inhibition concentration (IC₅₀) of various compounds, including niflumic acid (17 μM of IC₅₀) [14], flufenamic acid (28 μM of IC₅₀) [14], DIDS (48 μM of IC₅₀) [13], diphenylamine-2-carboxylate (DPC, 111 μM of IC₅₀) [13], 9-anthracene carboxylic acid (9-AC, 10.3 μM of IC₅₀) [13] and NPPB (22–68 μM of IC₅₀) [15]. But the potency of these blockers is relatively low. In other studies, CaCC current was evoked by direct intracellular injection of Ca²⁺ into an oocyte [12,16] or by depolarizing the membrane which allows Ca²⁺ entry through voltage gated Ca²⁺ channels [17-19]. However, these approaches can introduce complications of unstable baseline current due to irregular amplification of Ca²⁺ concentration upon Ca²⁺ entry, unpredictable con-

tribution of Ca²⁺ release from intracellular stores and time dependent inactivation of CaCCs, making it difficult to perform large scale drug screening. Based on the observation that no reliable method of drug screening and no ideal blocker of CaCC in *Xenopus laevis* oocytes have yet been described, we sought to design an optimized experimental protocol ideal for large scale drug screening to find better blockers for CaCCs.

Results

Cl⁻ current elicited by Ca²⁺ influx in oocytes permeabilized with ionomycin

To find optimal conditions for drug screening using CaCCs in *Xenopus* oocytes, we first characterized the CaCC currents in *Xenopus* oocytes and compared various treatment conditions. To permeabilize the oocyte membrane to allow Ca²⁺ influx, oocytes were treated with 10 μM ionomycin for 30 min in Ca²⁺ free solution. In oocytes, Ca²⁺ entry and activation of an inward current were achieved by switching from Ca²⁺ free external solution to Ca²⁺ containing solution [20]. After membrane permeabilization, application of external Ca²⁺ evoked Cl⁻ currents consisting of fast peak (I_{fast}) and slow steady state component (I_{slow}, Figure 1C) [20]. The fast component was elicited by 5 s exposure to extracellular Ca²⁺ ([Ca²⁺]_o) in a dose dependent manner (Figure 1A) and calculated EC₅₀ for [Ca²⁺]_o was 4.89 mM (n = 9) (Figure 1B). Therefore, 5 mM [Ca²⁺]_o was used to induce Cl⁻ current in all subsequent experiments. I_{fast} and I_{slow} were not induced by substituting Ca²⁺ with Ba²⁺ in each condition (Figure 1E, F, I, J, N, O), indicating that both of these currents were activated by Ca²⁺ entry.

In response to repetitive 5 s applications of the same dose of [Ca²⁺]_o, the amplitude of 2nd response was smaller compared to the initial response (I_{fast}^{2nd}/I_{fast}^{1st} = 0.89 ± 0.04, Figure 1M, white bar), most likely due to an activation of a Ca²⁺-dependent protein kinase C (PKC) [21]. To exclude the effect of PKC in CaCC current, PKC inhibitor chelerythrine was added to the intracellular solution. Inclusion of chelerythrine decreased the variability represented by the standard error of mean value (I_{fast}^{2nd}/I_{fast}^{1st} = 0.85 ± 0.013, Figure 1M, black bar), but still the 2nd response remained smaller than the 1st response (Figure 1D). Additional variability in peak amplitude can come from the Ca²⁺ induced Ca²⁺ release from intracellular stores. To eliminate the contribution of Ca²⁺ release from intracellular stores, Ca²⁺ ATPase inhibitor, thapsigargin was treated on ionomycin pretreated oocytes. Under the condition of ionomycin treatment followed by thapsigargin treatment and recording with chelerythrine added intracellular solution, the peak amplitudes of two consecutive responses to 5 mM external Ca²⁺ were almost the same with relatively low standard error of mean value (Figure 1H, I_{fast}^{2nd}/I_{fast}^{1st} = 1.01 ± 0.02 (n = 7), Figure 1M,




Figure 1
Endogenous Ca²⁺ activated Cl⁻ channels in *Xenopus laevis* oocyte. (A) Currents induced by extracellular Ca²⁺ in a dose dependent manner on ionomycin treated oocyte. (B) Dose response and EC₅₀ of Ca²⁺ obtained from (A). (C~F) Currents recorded after treatment of ionomycin without thapsigargin treatment. (C, G) Fast peak and slow component during Ca²⁺ applications. (G~J) Currents recorded after treatment of ionomycin followed by thapsigargin. (D, H) Second application of Ca²⁺ induces slightly reduced fast peak amplitude compared to the first peak. (E, I) Ba²⁺ does not induce the slow component. (F, J) Ba²⁺ does not induce the fast peak. (K~O) Comparison of currents under each condition. CHE+ means that current was measured with chelerythrine added intracellular solution. TG+ indicates that thapsigargin was treated on ionomycin pretreated oocytes. (K) Fast peak amplitude. (L) Slow component amplitude. (M) Summary of the experiments shown in (D) and (H); Ratio of amplitude induced by the first and the second Ca²⁺. (N) Summary of the experiments shown in (E) and (I). (O) Summary of the experiments shown in (F) and (J). n indicates number of oocytes. Error bars indicate SEMs. * indicates statistically significant difference by two-tailed t-test. *, p < 0.05; **, p < 0.01; ***, p < 0.001

gray bar). Therefore, a reliable protocol for drug screening of CaCCs in *Xenopus* oocytes was established with treatment of 1 μ M thapsigargin for 90 min to ionomycin treated oocytes followed by recording with microelectrodes filled with intracellular solution containing 1 μ M chelerythrine.

Effect of known blockers and commercially available chemical compounds on CaCC in *Xenopus* oocytes

Using the optimized drug screening protocol, the effect of known blockers of CaCC was tested. Over the concentration range tested (1 μ M – 300 μ M), each of the typical CaCC blockers caused a concentration dependent block of CaCC currents (Figure 2A) and IC_{50} s were obtained from the dose-response curves (Figure 2B). The name and structure for each chemical compound are listed in Figure 3, and each chemical compound was numbered as shown on top of each chemical structure. From the recordings, IC_{50} s were found to be 10.7 μ M for DIDS, 32.3 μ M for NPPB, 94.3 μ M for 9-AC, 37.3 μ M for niflumic acid, and 35.4 μ M for flufenamic acid (Figure 2C, Figure 3A, Table 1). Other blockers generally known for other Cl⁻ channels were also tested under the same condition. IC_{50} s were found to be 44.5 μ M for mefenamic acid and 88.1 μ M for *N*-Phenylanthranilic acid. Except for DIDS, most of known blockers displayed higher IC_{50} values compared to the previously reported values (Table 1).

We searched for other commercially available chemical compounds that have similar structure to known block-

ers. Since flufenamic acid, mefenamic acid and *N*-Phenylanthranilic acid commonly have anthranilic acid backbone, which is composed of two benzene rings, anthranilic acids containing a nitro group (-NO₂) such as 5-Nitro-*N*-phenylanthranilic acid (a-8), *N*-(2-Nitrophenyl)anthranilic acid (b-1) and *N*-(3-Nitrophenyl)anthranilic acid (b-2) were tested (Figure 3A, B). IC_{50} s were 42.5 μ M for a-8 and 32.1 μ M for b-2. b-1 showed low potency for CaCC block (Figure 3A, B, Table 1). Interestingly, even though a-8, b-1 and b-2 have a similar chemical composition, their blocking effect on CaCC was quite different. The only difference between three chemical compounds is the position of -NO₂. Therefore, the position of substituent group on benzene ring of the anthranilic acid backbone apparently affected the blocking effect on CaCC.


Positional effect of substituent group of benzene ring on block of CaCC current

To examine the positional effect of -NO₂ of benzene ring on block of CaCC current in more detail, we synthesized compounds with substitutions on the benzene ring (see additional file 1). We synthesized *N*-(4-nitrophenyl)anthranilic acid (b-3) that has -NO₂ on its *para* position and tested for the block of CaCC current. This compound showed a significantly improved IC_{50} of 17.8 μ M, compared to b-1 that has -NO₂ on its *ortho* position (IC_{50} > 200 μ M) or b-2 that has -NO₂ on its *meta* position (IC_{50} = 32.1 μ M Figure 4A). Based on the fact that blocking effects of -NO₂ on the benzene ring of either side of

Table 1: IC_{50} s of known blockers and anthranilic acid derivatives.

Compound number	Chemical compound	IC_{50} *	IC_{50}	n
a-1	DIDS	48	10.7	6
a-2	NPPB (5-nitro-2-(3-phenylpropylamino)benzoic acid)	22–68	32.3	6
a-3	9-AC (9-anthracene carboxylic acid)	10.3	94.3	5
a-4	Niflumic acid	17	37.3	7
a-5	Flufenamic acid (<i>N</i> -(3-Trifluoromethylphenyl)anthranilic acid)	28	35.4	6
a-6	Mefenamic acid		44.5	6
a-7	<i>N</i> -Phenylanthranilic acid		88.1	6
a-8	5-Nitro- <i>N</i> -phenylanthranilic acid		42.5	8
b-1	<i>N</i> -(2-Nitrophenyl)anthranilic acid		LP	7
b-2	<i>N</i> -(3-Nitrophenyl)anthranilic acid		32.1	7
b-3	<i>N</i> -(4-Nitrophenyl)anthranilic acid		17.8	6
b-4	5-Nitro- <i>N</i> -(4-nitrophenyl)anthranilic acid		15.4	5
b-5	<i>N</i> -(2-Trifluoromethylphenyl)anthranilic acid		29.5	6
b-6	<i>N</i> -(4-Trifluoromethylphenyl)anthranilic acid		6.0	6
b-7	<i>N</i> -(4-Fluoro-3-trifluoromethylphenyl)anthranilic acid		14.7	6
c-1	<i>N</i> -(4-Fluorophenyl)anthranilic acid		63.1	6
c-2	<i>N</i> -(4-Chlorophenyl)anthranilic acid		11.3	6
c-3	<i>N</i> -(4-Methylphenyl)anthranilic acid		55.3	7
c-4	<i>N</i> -(4-Isopropylphenyl)anthranilic acid		17.0	6
c-5	<i>N</i> -(4- <i>tert</i> -Butylphenyl)anthranilic acid		22.9	7
c-6	<i>N</i> -(4-Decylphenyl)anthranilic acid		LP	6
c-7	<i>N</i> -(4-Methoxyphenyl)anthranilic acid		102.3	5

IC_{50} * means IC_{50} previously studied. LP: Low Potency. IC_{50} > 200 μ M n indicates number of oocytes.

**Figure 2**

Effect of known blockers on Ca²⁺ activated Cl⁻ channel. (A) Trace of Ca²⁺ activated Cl⁻ channel current before and during application of flufenamic acid (FA). (B) Dose response relation of flufenamic acid block of Ca²⁺ activated Cl⁻ current. (C) Summary of IC₅₀s of commercially available blockers for Ca²⁺-activated Cl⁻ channel. n indicates number of oocytes. Error bars indicate SEMs.

anthranilic acid backbone (a-8, b-3) showed improved IC₅₀ compared to the N-Phenylanthranilic acid itself (a-7), we synthesized 5-Nitro-N-(4-nitrophenyl)anthranilic acid (b-4) that has -NO₂ on its *para* position on both benzene rings. Interestingly, IC₅₀ of b-4 was further enhanced (IC₅₀ = 15.4 μM) than a-8 and b-3, indicating that substituent group on *para* position should enhance the blocking effect.

Since flufenamic acid (N-(3-trifluoromethylphenyl)anthranilic acid, a-5) has trifluoromethyl group (-CF₃) in *meta* position, we hypothesized that shifting -CF₃

from *meta* position to *ortho* or *para* position would result in changes in IC₅₀. We synthesized N-(2-trifluoromethylphenyl)anthranilic acid (b-5) that has -CF₃ on its *ortho* position and N-(4-trifluoromethylphenyl)anthranilic acid (b-6) that has -CF₃ on its *para* position. b-5 showed enhanced IC₅₀ (IC₅₀ = 29.5 μM) than a-5 (Figure 3B, 4B). In particular, b-6 dramatically enhanced the IC₅₀ compared to any other compounds (IC₅₀ = 6.0 μM, Figure 3B, 4B). These data indicate that changing the position of substituent group on the benzene ring of anthranilic acid backbone to *para* position leads to an increase in blocking activity.





Figure 3
Chemical structures and IC₅₀s of known blockers and anthranilic acid derivatives. (A) Known blockers. (B) Anthranilic acid derivatives; positional compounds. (C) Anthranilic acid derivatives that have variable substituent group on *para* position of benzene ring. LP: Low Potency. IC₅₀ > 200 μM. n indicates number of oocytes.

**Figure 4**

Positional effect of substituent group on the phenyl ring of blocker that affects block of Ca²⁺-activated Cl⁻ current. (A) Comparison of chemical structure, IC₅₀ and dose response between *N*-(2-nitrophenyl)anthranilic acid, *N*-(3-nitrophenyl)anthranilic acid and *N*-(4-nitrophenyl)anthranilic acid in which the nitro (-NO₂) group on the benzene ring is positioned at *ortho*, *meta* and *para* position. (B) Comparison of chemical structure, IC₅₀ and dose response between flufenamic acid and derivatives *N*-(2-trifluoromethylphenyl)anthranilic acid and *N*-(4-trifluoromethylphenyl)anthranilic acid in which the trifluoromethyl (-CF₃) group on the benzene ring is positioned at *ortho*, *meta* and *para* position. Shaded boxes indicate the substituent groups tested. n indicates number of oocytes. Error bars indicate SEMs.

Comparison of blocking effect about anthranilic acid derivatives on CaCC

Since *para* positioned anthranilic acid derivatives showed higher potency of block, we synthesized more anthranilic acid derivatives that have various substituents on *para*

position of the benzene ring and tested on CaCC currents. However, blocking activity of these derivatives was not better than b-5 with -CF₃ on *para* position as indicated by their IC₅₀s: c-2 (chloryl group, -Cl, IC₅₀ = 11.3 μM), c-4 (isopropyl group, -C₃H₇, IC₅₀ = 17.0 μM) and c-5 (butyl

group, -C₄H₉, IC₅₀ = 22.9 μM (Figure 3C, Table 1). In addition, *N*-(4-Fluorophenyl)-anthranilic acid (*c*-1, IC₅₀ = 63.1 μM), *N*-(4-Methylphenyl)-anthranilic acid (*c*-3, IC₅₀ = 55.3 μM), *N*-(4-Decylphenyl)-anthranilic acid (*c*-6, IC₅₀ > 200 μM) and *N*-(4-Methoxyphenyl)-anthranilic acid (*c*-7, IC₅₀ = 102.3 μM) which have fluoro group (-F), methyl group (-CH₃), decyl group (-CH₂(CH₂)₈CH₃) and methoxy group (-OCH₃) showed relatively low potency for CaCC block, respectively (Figure 3C, Table 1). Therefore, the most potent derivative among the compounds tested was the *N*-(4-trifluoromethylphenyl)anthranilic acid that has -CF₃ on its *para* position with IC₅₀ of 6.0 μM.

Discussion

Since the lack of useful tools for drug screening has impeded the development of better blocker for CaCCs, we designed an improved drug screening protocol utilizing endogenous CaCCs in *Xenopus* oocytes. Our newly designed protocol consists of *Xenopus Leavis* oocytes treated with ionomycin and thapsigargin followed by recording with intracellular solution containing chelerythrine. These manipulations provide a consistent induction of CaCC mediated currents with similar amplitude upon repeated application of 5 mM external Ca²⁺. Treatment of ionomycin allows constant entry of Ca²⁺ from extracellular solution, whereas thapsigargin prevents irregular concentration fluctuations caused by Ca²⁺ release amplification from internal stores. Elevation of intracellular Ca²⁺ due to Ca²⁺ influx through Ca²⁺ channels formed by ionomycin should cause inactivation of the CaCC conductance via activation of PKC [21]. Thus, inhibition of PKC should decrease the channel modulation by PKC phosphorylation, which was shown to modulate the CaCC current [22]. Thus, intracellular solution containing PKC inhibitor chelerythrine was used for recording of CaCC current to exclude the effect of PKC. Under these conditions, the intracellular Ca²⁺ concentration was kept constant during induction of CaCC current, and current rundown due to PKC inactivation was kept at minimal level. These manipulations made it possible to measure blocking effect of various compounds on CaCC-mediated current in *Xenopus leavis* oocytes more accurately.

In addition, some blockers such as niflumic acid change the intracellular Ca²⁺ buffering which causes an increase in intracellular Ca²⁺ concentration [7-11]. Since Cl⁻ current is induced exclusively by external Ca²⁺ in our protocol, we were able to isolate the blocking effect of various compounds on channel activities from the effect of compounds on Ca²⁺ buffering capacity.

Utilizing this optimized protocol, we first compared the effect of known blockers of CaCC. We found that IC₅₀s of DIDS, NPPB, 9-AC, niflumic acid and flufenamic acid on CaCC current in *Xenopus* oocytes were 10.7 μM (DIDS),

32.3 μM (NPPB), 94.3 μM (9-AC), 37.3 μM (niflumic acid) and 35.4 μM (flufenamic acid), whereas previously reported values are 48 μM, 28–68 μM, 10.3 μM, 17 μM and 28 μM, respectively (see Table 1). Blocking effect of each known blocker differed from previous reports. It is likely due to differences in our protocol. We suggest that our modified screening protocol provides more exact profile of CaCC blocker on CaCC in *Xenopus Leavis* oocytes due to the reliability and repeatability of our assay protocol. In addition, some blockers that were generally used for other Cl⁻ channels such as mefenamic acid and *N*-Phenylanthranilic acid showed comparable blocking effect on CaCC in *Xenopus Leavis* oocytes with IC₅₀s of 44.5 μM and 88.1 μM.

Based on the fact that several known blockers of CaCCs have structural similarity as anthranilic acid which is composed of two benzene rings, we searched for CaCC blocker candidates with the structural similarity among commercially available chemical compounds. Even though, the number of compounds were not enough to explain exact SAR (structure-activity relationship), we could figure out the correlation between biological activity and the kind and position of substituents. We found that 5-Nitro-*N*-phenylanthranilic acid and *N*-(3-Nitrophenyl)anthranilic acid both showed similar level of blocking effect as niflumic acid or flufenamic acid. Interestingly, blocking potency was quite different between *N*-(3-Nitrophenyl)anthranilic and *N*-(2-Nitrophenyl)anthranilic acid even though their chemical composition is identical, except for the relative position of -NO₂ in the benzene ring. This reflected that the position of -NO₂ affected the blocking activity to CaCC. Synthesized *N*-(4-Nitrophenyl)anthranilic acid that has -NO₂ on its *para* position showed improved blocking ability compare to *N*-(3-Nitrophenyl)anthranilic and *N*-(2-Nitrophenyl)anthranilic acid with -NO₂ on *meta* and *ortho* position, respectively. Likewise, synthesized *N*-(4-trifluoromethylphenyl)anthranilic acid that has -CF₃ on its *para* position blocked CaCC better than flufenamic acid (*N*-(3-trifluoromethylphenyl)anthranilic acid) and *N*-(2-trifluoromethylphenyl)anthranilic acid with -CF₃ on *meta* and *ortho* position, respectively. These results suggested that the positioning of substituent group on *para* site contributes to a higher affinity of these compounds to CaCC. Therefore, we concluded that anthranilic acid derivatives containing *para* positioned substituent group have high potency of CaCC block.

Additionally synthesized chemical compounds are anthranilic acid derivatives that have various substituent groups such as various hydrocarbons introduced into the benzene ring at *para* position. IC₅₀s of *N*-(4-Chlorophenyl)-anthranilic acid, *N*-(4-Isopropylphenyl)-anthranilic acid and *N*-(4-*tert*-Butylphenyl)-anthranilic acid were

similar in IC_{50} of *N*-(4-Nitrophenyl)anthranilic acid. However, low blocking effect was shown in *N*-(4-Fluorophenyl)-anthranilic acid, *N*-(4-Methylphenyl)-anthranilic acid and *N*-(4-Decylphenyl)-anthranilic acid. These results suggested that there should be no strong correlation between blocking effect and size of substituent group in CaCC blockers. It has been reported that blocker size affects voltage dependence rather than potency of CaCC block because large blockers lodge at sites less deep in the channel [1]. Taken together, *N*-(4-trifluoromethylphenyl)anthranilic acid that has $-CF_3$ on its *para* position in one benzene ring is most potent CaCC blocker candidate so far.

Ion channels endogeneously expressed in *Xenopus Laevis* oocytes have extensively used in biological and pharmacological research. CaCCs in *Xenopus Laevis* oocytes have similar properties in many ways to those in other tissue. It has been revealed that several human diseases are involved in CaCCs. However, its molecular identity is not clear yet. Recently, CLCA [23,24], bestrophin [25], tweety [26] and TMEM16A [27] have been proposed as the molecular candidates. It is important to note that blocker candidates confirmed in *Xenopus Laevis* oocytes should be also examined in these candidate molecules and CaCCs in other various tissues. Nevertheless, several common blockers for CaCCs have undesirable side effects: they can affect the cellular Ca^{2+} level [7-11], and block VRACs [3] and K^+ channels [5,6]. Recent study also identified that niflumic acid, flufenamic acid and Indomethacin are non-steroidal anti-inflammatory drug (NSAID) that have inhibitor potencies against both cyclo-oxygenase (COX) 1 and 2 [28]. Considering the structural similarity, other candidates of CaCC blocker may have the similar side effects. Therefore, future experiments should be followed to test whether blocker candidates show decreased side effects.

Conclusion

This study has shown the development of reliable screening method for CaCC blocker using endogeneous CaCCs in *Xenopus laevis* oocytes. We found that anthranilic acid derivatives containing *para* positioned substituent group have high potency of CaCC block and *N*-(4-trifluoromethylphenyl)anthranilic acid is most effective CaCC blocker among the synthesized chemical compounds.

Methods

Preparation of oocytes

Matured stage V-VI oocytes [29] harvested from adult *Xenopus laevis* females (*Xenopus I*, Michigan, USA) which were maintained in an automated maintenance system, Xenopus System (Aquatic Habitats, Florida, USA). The animals were anaesthetized by cooling with ice [30]. Ovarian follicles were surgically removed, treated with 2

mg/ml collagenase type IA at room temperature for 90 min in Ca^{2+} free Barth's solution containing 89 mM NaCl, 1.0 mM KCl, 2.4 mM $NaHCO_3$, 0.82 mM $MgSO_4$ and 10 mM HEPES (pH 7.4). The oocytes were extensively rinsed with normal Barth's solution containing 88 mM NaCl, 1.0 mM KCl, 2.4 mM $NaHCO_3$, 0.82 mM $MgSO_4$, 0.33 mM $Ca(NO_3)_2$, 1.41 mM $CaCl_2$ and 5 mM HEPES (pH 7.4), placed in culture Barth's solution containing 88 mM NaCl, 1.0 mM KCl, 2.4 mM $NaHCO_3$, 0.82 mM $MgSO_4$, 0.33 mM $Ca(NO_3)_2$, 0.91 mM $CaCl_2$, 10 mM HEPES, 10 μ g/ml streptomycin and 10 μ g/ml penicillin (pH 7.4), and maintained at 18°C. Oocytes were used 1-4 days after isolation.

Synthesis

All commercially available chemicals were reagent grade and used as purchased unless stated otherwise. All reactions were performed under an inert atmosphere of dry argon or nitrogen using distilled dry solvents. Reactions were monitored by TLC analysis using Merck silica gel 60 F-254 thin layer plates. Flash column chromatography was carried out on Merck silica gel 60 (230-400 mesh) by preparative LC system. 1H and ^{13}C NMR spectra were recorded either on a spectrometer operating at Bruker 400 and 100 MHz, respectively. Preparations of chemicals are described in detail in Additional file 1.

Electrophysiology

To permeabilize the membrane to Ca^{2+} , oocytes were incubated in the oocyte recording solution containing 96 mM NaCl, 2 mM KCl, 2 mM $MgCl_2$, 0.5 mM EGTA and 10 mM HEPES (pH 7.4), added with 10 μ M ionomycin for 30 min. The ionomycin was then removed from the external solution by washing with oocyte recording solution. In case of thapsigargin treatment, ionomycin treated oocytes were subsequently incubated in the oocyte recording solution containing 1 μ M thapsigargin for 90 min. Then thapsigargin was also washed with the oocyte recording solution. Two electrode voltage-clamp recordings were made using Warner model OC725B two-electrode voltage clamp amplifier (Warner Instruments, Inc., Hamden, CT) with 1 M KCl-filled microelectrodes (WPI; Sarasota, FL; 1B150F-4) pulled with a P-97 programmable pipette puller (Sutter Instruments Co.; Novato, CA). The pipettes had resistances of 1-3 M Ω . During the recording oocytes were continuously perfused with oocyte recording solution. All recordings were from a holding potential of -60 mV. Drugs were prepared in separate bottles and applied by gravity. Flow of solutions was approximately 1 ml/min.

Chemicals

Chemical compounds including the following reagents were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA); Collagenase type 1A, ionomycin- Ca^{2+} salt, thapsi-

gargin, chelerythrine. HEPES (N-[2-hydroxyethyl]piperazine-N'-[ethanesulfonic acid]) was obtained from J.T Baker (Mallinckrodt Baker, Inc. Phillipsburg, NJ, USA).

Analysis of data

Currents were digitally recorded with AxoScope software (Axon Instruments, Burlingame, CA, USA) and data analysis was done with SigmaPlot 10.0 (Systat Software, Inc., CA, USA). All the current responses during a blocker were normalized to the average of a Ca²⁺ induced Cl⁻ current applied before blocker application. Normalized and average data were fitted to the SigmaPlot's Logistic, 3 Parameter curve to determine dose-response relationship and IC₅₀. All data are expressed as mean ± standard error of mean and statistical analysis was performed using a 2-tailed t-test.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SJO carried out electrophysiological recordings, data analysis and manuscript preparation. JHP, JKL and EJR designed and synthesized chemical compounds. SKH participated in electrophysiological recordings and synthesis of chemical compounds. CJL conceived the idea, coordinated the study, carried our data interpretation and drafted the manuscript. All authors have read and approved the manuscript.

Additional material

Additional file 1

Methods for synthesis of anthranilic acid derivatives.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1756-6606-1-14-S1.doc>]

Acknowledgements

We thank to Dayoung Cho for her contribution to drug screening.

This work was supported by the Korea research foundation KRF-2005-070-C00096 (C.J.L), KIST Core Competency Program and KIST Institutional Program.

References

- Hartzell C, Putzier I, Arreola J: **Calcium-activated chloride channels.** *Annu Rev Physiol* 2005, **67**:719-758.
- Frings S, Reuter D, Kleene SJ: **Neuronal Ca²⁺-activated Cl⁻ channels – homing in on an elusive channel species.** *Prog Neurobiol* 2000, **60**:247-289.
- Xu WX, Kim SJ, So I, Kang TM, Rhee JC, Kim KW: **Volume-sensitive chloride current activated by hyposmotic swelling in antral gastric myocytes of the guinea-pig.** *Pflügers Arch* 1997, **435**(1):9-19.
- Greenwood IA, Large WA: **Properties of a Cl⁻ current activated by cell swelling in rabbit portal vein vascular smooth muscle cells.** *Am J Physiol* 1998, **275**(5 Pt 2):H1524-H1532.
- Wang HS, Dixon JE, McKinnon D: **Unexpected and differential effects of Cl⁻ channel blockers on the Kv4.3 and Kv4.2 K⁺ channels. Implications for the study of the I(to2) current.** *Circ Res* 1997, **81**:711-718.
- Greenwood IA, Leblanc N: **Overlapping pharmacology of Ca²⁺-activated Cl⁻ and K⁺ channels.** *Trends Pharmacol Sci* 2007, **28**(1):1-5.
- Poronnik P, Ward MC, Cook DI: **Intracellular Ca²⁺ release by flufenamic acid and other blockers of the non-selective cation channel.** *FEBS Lett* 1992, **296**:245-248.
- Reinsprecht M, Rohn MH, Spadinger RJ, Pecht I, Schindler H, Romanin C: **Blockade of capacitive Ca²⁺ influx by Cl⁻ channel blockers inhibits secretion from rat mucosal-type mast cells.** *Mol Pharmacol* 1995, **47**:1014-1020.
- Shaw T, Lee RJ, Partridge LD: **Action of diphenylamine carboxylate derivatives, a family of non-steroidal anti-inflammatory drugs, on [Ca²⁺]_i and Ca²⁺-activated channels in neurons.** *Neurosci Lett* 1995, **190**:121-124.
- Schultheiss G, Frings M, Hollingshaus G, Diener M: **Multiple action sites of flufenamate on ion transport across the distal colon.** *Br J Pharmacol* 2000, **130**:875-885.
- Partridge LD, Valenzuela CF: **Block of hippocampal CAN channels by flufenamate.** *Brain Res* 2000, **867**:143-148.
- Miledi R, Parker J: **Chloride current induced by injection of calcium into *Xenopus* oocytes.** *J Physiol (Lond)* 1984, **357**:173-183.
- Qu Z, Hartzell HC: **Functional geometry of the permeation pathway of Ca²⁺-activated Cl⁻ channels inferred from analysis of voltage-dependant block.** *J Biol Chem* 2001, **276**:18423-18429.
- White MM, Aylwin M: **Niflumic and flufenamic acids are potent reversible blockers of Ca²⁺-activated Cl⁻ channels in *Xenopus* oocytes.** *Mol Pharmacol* 1990, **37**:720-724.
- Wu G, Hamill OP: **NPPB block of Ca²⁺-activated Cl⁻ channels in *Xenopus* oocytes.** *Pflügers Arch* 1992, **420**:227-229.
- Dascal N, Gillo B, Lass Y: **Role of calcium mobilization in mediation of acetylcholine-evoked chloride currents in *Xenopus laevis* oocytes.** *J Physiol* 1985, **366**:299-313.
- Miledi R: **A calcium-dependent transient outward current in *Xenopus laevis* oocytes.** *Proc R Soc Lond B Biol Sci* 1982, **215**(1201):491-497.
- Barish ME: **A transient calcium-dependent chloride current in the immature *Xenopus* oocytes.** *J Physiol* 1983, **342**:309-325.
- Dascal N, Snutch TP, Lübbert H, Davidson N, Lester HA: **Expression and modulation of voltage-gated calcium channels after RNA injection in *Xenopus* oocytes.** *Science* 1986, **231**:1147-50.
- Boton R, Gillo B, Dascal N, Lass Y: **Two calcium-activated chloride conductance in *Xenopus laevis* oocytes permeabilized with the ionophore A23187.** *J Physiol (Lond)* 1989, **408**:511-534.
- Boton R, Singer D, Dascal N: **Inactivation of calcium-activated chloride conductance in *Xenopus* oocytes: roles of calcium and protein kinase C.** *Pflügers Arch* 1990, **416**:1-6.
- Hahnenkamp K, Durieux ME, van Aken H, Berning S, Heyse TJ, Höne-mann CW, Linck B: **Modulation of *Xenopus laevis* Ca²⁺-activated Cl⁻ currents by protein kinase C and protein phosphatases: implications for studies of anesthetic mechanisms.** *Anesth Analg* 2004, **99**:416-422.
- Gandhi R, Elble RC, Gruber AD, Ji HL, Copeland SM, Fuller CM, Pauli BU: **Molecular and functional characterization of a calcium-sensitive chloride channel from mouse lung.** *J Biol Chem* 1998, **273**:32096-32101.
- Gruber AD, Elble RC, Ji HL, Schreur KD, Fuller CM, Pauli BU: **Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca²⁺-activated Cl⁻ channel proteins.** *Genomics* 1998, **54**:200-214.
- Sun H, Tsunenari T, Yau KW, Nathans J: **The vitelliform macular dystrophy protein defines a new family of chloride channels.** *Proc Natl Acad Sci USA* 2002, **99**(6):4008-13.
- Suzuki M, Mizuno A: **A novel human Cl⁻ channel family related to *Drosophila* flightless locus.** *J Biol Chem* 2004, **279**(21):22461-8.
- Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee J, Lee B, Kim BM, Raouf R, Shin YK, Oh U: **TMEM16A confers**

- receptor-activated calcium-dependent chloride conductance. *Nature* 2008, **455(7217)**:1210-1215.
28. Ouellet M, Falgout JP, Percival MD: **Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms.** *Biochem J* 2004, **377**:675-684.
 29. Dumont JN: **Oogenesis in *Xenopus laevis* (Daudin). I. Stages of oocyte development in laboratory maintained animals.** *J Morphol* 1972, **136(2)**:153-179.
 30. Yoshida S, Plant S: **Mechanism of release of Ca²⁺ from intracellular stores in response to ionomycin in oocytes of the frog *Xenopus laevis*.** *J physiol* 1992, **458**:307-318.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

